CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague.
The current U.S. Department of Defense candidate plague vaccine is a fusion between two Yersinia pestis proteins: the F1 capsular protein, and the low calcium response (Lcr) V-protein. We hypothesized that an immunomodulator, such as CpG oligodeoxynucleotide (ODN)s, could augment the immune response to the plague F1-V vaccine in a mouse model for plague. CpG ODNs significantly augmented the antibody response and efficacy of a single dose of the plague vaccine in murine bubonic and pneumonic models of plague. In the latter study, we also found an overall significant augmentation the immune response to the individual subunits of the plague vaccine by CpG ODN 2006. In a long-term, prime-boost study, CpG ODN induced a significant early augmentation of the IgG response to the vaccine. The presence of CpG ODN induced a significant increase in the IgG2a subclass response to the vaccine up to 5 months after the boost. Our studies showed that CpG ODNs significantly augmented the IgG antibody response to the plague vaccine, which increased the probability of survival in murine models of plague (P<0.0001).
Bacteriology Division, United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, Frederick, MD 21702, United States. kei.amemiya@us.army.mil
Kei
K
Amemiya
Jennifer L
JL
Meyers
Taralyn E
TE
Rogers
Randy L
RL
Fast
Anthony D
AD
Bassett
Patricia L
PL
Worsham
Bradford S
BS
Powell
Sarah L
SL
Norris
Arthur M
AM
Krieg
Jeffrey J
JJ
Adamovicz
D000276:Adjuvants, Immunologic; D000818:Animals; D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial / Q000276:immunology*; D001426:Bacterial Proteins / Q000276:immunology*; D005260:Female; D051379:Mice; D008807:Mice, Inbred BALB C; D009838:Oligodeoxyribonucleotides / Q000276:immunology*; D010930:Plague / Q000276:immunology / Q000517:prevention & control*; D010931:Plague Vaccine / Q000276:immunology*; D052899:Pore Forming Cytotoxic Proteins / Q000276:immunology*; D051195:Toll-Like Receptor 2 / Q000502:physiology; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000276:immunology; D015010:Yersinia pestis / Q000276:immunology
D000276:Adjuvants, Immunologic; D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001426:Bacterial Proteins; C408982:CPG-oligonucleotide; C043908:LcrV protein, Yersinia; D009838:Oligodeoxyribonucleotides; D010931:Plague Vaccine; D052899:Pore Forming Cytotoxic Proteins; C493486:Tlr2 protein, mouse; D051195:Toll-Like Receptor 2; D014614:Vaccines, Synthetic; C086725:caf1 protein, Yersinia pestis